Form 4: Zimmer Biomet Director Reports Phantom Stock Acquisition
Statement of Changes in Beneficial Ownership
Director Sreelakshmi Kolli acquired 175.404 phantom stock units under the company's deferred compensation plan.
Summary
- Director Sreelakshmi Kolli acquired 175.404 phantom stock units on March 31, 2026.
- The units were acquired under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
- The conversion price for these units is 1-for-1.
- The total beneficial ownership following this transaction is 5,769.994 phantom stock units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant market sentiment impact.
Positives
- Director demonstrates alignment with company performance through participation in the deferred compensation plan.
Negatives
- None identified.
Risks
- Value of phantom stock units is tied to the future performance of Zimmer Biomet common stock.
Future Outlook
The phantom stock units are set to be settled in shares of company common stock within sixty days after the cessation of the reporting person's service as a Director.
Management Comments
- The transaction reflects standard participation in the company's deferred compensation plan for non-employee directors.
Industry Context
StockSavvy.ai notes that director participation in deferred compensation plans is a standard corporate governance practice in the medical device industry, signaling long-term commitment to the issuer's equity performance.
Comparison to Industry Standards
- The use of phantom stock units for director compensation is consistent with peer companies in the healthcare and medical technology sectors such as Stryker or Medtronic.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard director compensation event.
Next Steps
- Settlement of units into common stock upon the director's eventual departure from the board.
Key Dates
| Date | Description |
|---|---|
| 01/30/2026 | Accrual of 15.067 phantom stock units via dividend reinvestment. |
| 03/31/2026 | Transaction date for the acquisition of 175.404 phantom stock units. |
| 04/02/2026 | Filing date of the Form 4. |
Keywords
Zimmer Biomet, ZBH, Form 4, Insider Trading, Director Compensation, Phantom Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.